Immunome (IMNM) Current Deferred Revenue (2023 - 2025)

Immunome has reported Current Deferred Revenue for 3 years, with the latest figure at $4.0 million in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue fell 68.5% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2025 stood at $4.0 million (down 68.5% YoY), and the FY2024 full-year result was $6.9 million, down 56.57% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $4.0 million, down from $6.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $27.6 million in Q1 2023, with the low at $4.0 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $14.4 million across 3 years, with a median of $12.7 million in 2024.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 42.92% — and 2025, when it slumped 68.5%.
• Immunome's Current Deferred Revenue stood at $16.0 million in 2023, then plunged by 56.57% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
• The last three Current Deferred Revenue figures came in at $4.0 million (Q1 2025), $6.9 million (Q4 2024), and $9.7 million (Q3 2024), per Business Quant data.